跳至主要内容
临床试验/NCT01426594
NCT01426594Unknown不适用

Real-life Experience of the Use of Isomers as METPURE XL (S (-) Metoprolol Succinate) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients

Closter Pharma1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2011年8月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
2,000
试验地点
1
主要终点
Effect of therapy in the management of cardiovascular diseases

研究概览

简要总结

This is a Phase 4, observational, open study in patients who their doctor has prescribe METPURE XL (S (-)metoprolol succinate)by clinical practice. No medication was provided by the sponsor. The planned observation time is 8 weeks. The 8 weeks of observation involves an evaluation of baseline followed by information gathered from the assessment visits at week 4 and week 8.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who were prescibed with s(-)metoprolol succinate(25mg, 50mg), depending on their clinical condition and use locally approved will be eligible to participate in this study

排除标准

  • 未提供

结局指标

主要结局

Effect of therapy in the management of cardiovascular diseases

时间窗: 8 weeks

The objective is to mesure the effect of Metpure XL in cadiovascular diseases as hypertension, post MI and coronary disease

次要结局

  • Evaluate and compare the rate of compliance with treatment(8 weeks)
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability(8 weeks)

研究者

发起方
Closter Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验